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the other with Kd = 710 nM and about 3 X 106 sites per cell. Sera from various species, human amniotic fluid, and certain tissue extracts inhibited specific binding of [3H]P(Bu)2. Fractionation of human serum led to a 135-fold purification of an inhibitory factor with a molecular weight in the range 40,000 to 80,000.
In contrast to chemicals that initiate the carcinogenic process apparently by binding covalently to cellular DNA, the primary site of action of the phorbol ester tumor promoters appears to be the cell surface membrane (for review, see refs. 1 and 2). In previous papers (3, 4) from this laboratory, it was postulated that the potent tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) actually binds to and usurps the function of a membrane-associated receptor that is normally utilized by an endogenous polypeptide growth factor. Indirect evidence for this hypothesis includes the facts that: (a) TPA and related compounds act in a concentration range similar to that of several hormones and growth factors (i.e., 0.1-10 nM), (b) these compounds display similar structure-function requirements on cells from diverse species and tissues, and (c) like known hormones, they induce highly pleiotropic effects which vary considerably depending upon the target cell (3, 4) . The fact that the earliest cellular responses to these agents occur at the cell surface membrane (1, 2) suggested that the putative receptors were associated with the plasma membrane (2-4).
Utilizing [3H] TPA, however, we were not able to demonstrate the existence of a specific saturable receptor in intact HeLa cells but we were concerned that these receptors might have been masked by the nonspecific partitioning of the highly hydrophobic TPA into lipid phases of the cell (5) . Recently, Blumberg and his colleagues utilized [3H]phorbol dibutyrate [P(Bu)2j, which is much less hydrophobic, to overcome this problem and obtained direct evidence of specific high-affinity saturable receptors in crude membrane preparations ofchicken embryo fibroblasts (6) and mouse epidermis (7) .
In the present study, we utilized [3H]P(Bu)2 to demonstrate cell surface receptors for this class of compounds in intact cell monolayers of rat embryo fibroblast cultures. This paper describes several properties of these receptors and also provides evidence that mammalian sera and tissue extracts contain a factor that inhibits [3H]P(Bu)2 binding.
MATERIALS AND METHODS
Materials. The rat embryo cells (CREF) used are a subelone ofthe Fischer cell line, isolated by Paul Fisher in this laboratory (8) . Cell culture media were from GIBCO.
[3H]P(Bu)2 (specific activity, 6.4 Ci/mmol; 1 Ci = 3.7 x 10'°becquerels) and unlabeled P(Bu)2 were from Lifesystems Company (Newton, MA). Other phorbol compounds were from Consolidated Midland (Brewster, NY). Teleocidin B was a gift of T. Sugimura. Epidermal growth factor (EGF) and fibroblast growth factor were from Collaborative Research (Waltham, MA). Platelet-derived growth factor, platelet-poor plasma derived serum, and lipoprotein-depleted human serum were gifts from Larry Witte and DeWitt Goodman. Human serum albumin was a gift from Van der Sande (New York Blood Center). Animal sera were obtained from normal animals. Pooled human serum was obtained from normal donors. Human amniotic fluid, human pregnancy urine, and human cerebrospinal fluid were identified by number code to preserve confidentiality. Rat embryo and adult rat liver extracts were prepared at 4°C by homogenizing the tissue in an equal volume of 0.3 M sucrose/10 mM Tris HCl, pH 7.4, in a Polytron homogenizer. The homogenate was centrifuged at 10,000 X g for 30 min and the supernatant fraction was centrifuged at 100,000 X g for 60 min. The second supernatant fraction was then assayed for protein and for inhibition of[3H]P(Bu)2 binding. P(Bu)2 Binding Assay. CREF cells were grown in 5-cm plastic tissue culture dishes containing 5 ml of Dulbecco's modified Eagle's minimal essential medium plus 10% calfserum. Binding assays were conducted on 1 to 2 x 106 cells per dish. The monolayer was washed once with 5 ml of phosphate-buffered saline and 2 ml of assay buffer (2 vol of Dulbecco's medium plus 1 vol of buffered saline plus bovine serum albumin at 1 mg/ml) was added. For most experiments, the cell monolayer was then incubated for 60 min at 37°C prior to addition of3 nM [3H]P(Bu)2 and possible inhibitors. After this addition, the cells were usually incubated for 30 min at 37°C. The monolayer was then rapidly washed three times, with a total of 15 ml of ice-cold assay Abbreviations: TPA, 12-0-tetradecanoylphorbol 13-acetate; P(Bu)2, phorbol 12,13-dibutyrate; EGF, epidermal growth factor; ID50, concentration required for 50% inhibition of binding.
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buffer. The cells were solubilized for 2 hr at 370C in 1 ml of0.8% Triton X-100/0.02% EDTA/0.25% trypsin in buffered saline. The plates were then washed twice with 0.5 ml of 1% NaDodSO4. The solubilizing solution and washings were combined and assayed for radioactivity in 15 ml of Hydrofluor scintillation fluid (National Diagnostics Human serum was applied to a 10 X 2.5 cm column of Blue Sepharose C1-6B equilibrated with phosphate-buffered saline and eluted with the same saline at 1 ml/min. The material bound to the column, which was mainly albumin (9), was then eluted with 0.5 M NaCV50 mM Tris HCI, pH 8.0. Protein content was monitored by absorbance at 280 nm and fractions were tested directly for inhibitory activity in a [3H]P(Bu)2 binding assay. The major inhibitory activity eluted early from the column (prior to albumin) and was designated fraction 1. Fraction 1 was mixed with an equal volume ofpacked CM-Sephadex in 0.01 M sodium acetate buffer (pH 5.5). After 15 min at 0°C, the mixture was centrifuged and the supernatant fraction was reextracted with a second batch of CM-Sephadex. Material binding to the CM-Sephadex was eluted with 1.5 M NaCV50 mM Tris HCl, pH 7.4. Both fractions were dialyzed against phosphate-buffered saline and then assayed for inhibition of [ H]P(Bu)2 binding. To estimate molecular weight, a 3-ml sample offraction 1 was applied to a Sephadex G-100 column (26 x 1.5 cm) and eluted with buffered saline, and fractions were tested for inhibition of [3H]P(Bu)2 binding. The column was calibrated with proteins of known molecular weights.
Protein concentrations were determined by the Lowry method (10). Serum fractions were also analyzed by NaDodSO4 polyacrylamide gel electrophoresis on 10% acrylamide separation gel with 5% stacking gel (11) . RESULTS When CREF cell monolayers were incubated with 3 nM [3H]P(Bu)2 at 370C specific binding occurred rapidly and reached a maximum within 10 min (Fig. 1A) . Specific binding decreased slightly (24%) by 20 min but remained constant thereafter for at least 3 hr at 37°C. The decrease between 10 and 20 min was observed repeatedly but its significance is not known. At 4°C, specific [3H]P(Bu)2 binding was considerably slower, requiring 3 hr to reach a maximum. The plateau value at 40C was similar to that obtained at 370C. In this study and in all of the subsequent studies, we measured total binding and nonspecific binding of [3H]P(Bu)2 in parallel; nonspecific binding is that obtained in the presence of a vast excess (50 AM) of unlabeled P(Bu)2. The latter value was subtracted from the total binding to obtain the specific binding. Nonspecific Fig. 3 ; Table 2 ). Pooled normal human serum had an even greater effect, producing 50% inhibition of [3H]P(Bu)2 binding at a concentration of about 4 mg/ml (Fig. 3) . Human serum from platelet-depleted plasma was also active, suggesting that the inhibitory activity is not derived from platelets. This is consistent with the lack of activity ofplatelet-derived growth factor (Table 1) . Lipoprotein-depleted human serum was also active, suggesting that the effect did not reflect nonspecific trapping ofthe [3H]P(Bu)2 in serum lipids. Other biologic fluids that contained significant activity included rhesus monkey serum, pregnant rat serum, human amniotic fluid, rat embryo and rat liver homogenates (Table 2) . Cerebrospinal fluid and concentrated urine were negative. Although purified serum albumin did inhibit [3H]P(Bu)2 binding, this occurred only with concentrations 10-fold greater than those required with an equivalent amount of serum.
When CREF cells were incubated in serum the inhibition of (15) (16) (17) (18) . Fractionation of Serum. Human serum was fractionated by affinity chromatography, ion exchange, and gel filtration to partially purify the above factor (Table 3 ). In the chromatography on a Blue Sepharose CL-6B column, which retains albumin (9) , most of the inhibitory activity was found in the void volume.
Analysis of this material by NaDodSO4polyacrylamide gel electrophoresis indicated that it was virtually free of albumin. Fractionation on the Blue Sepharose column led to a 3-to 8-fold purification.
Further purification of the inhibitory factor was achieved by treating the Blue Sepharose fraction with CM-Sephadex at pH (Table 3 ). The total yield of inhibitory activity actually increased about 3-fold after these two partial purification steps, suggesting that whole serum contains a substance that prevents this factor from exerting its full activity.
Although gel electrophoresis indicated that al-antitrypsin was present in the CM-Sephadex fraction, a commercial preparation of al-antitrypsin lacked inhibitory activity even when tested at a protein concentration 5 times the ID50 of this fraction (Table   2 ). Fractionation on a Sephadex G-100 column indicated that the major peak of inhibitory activity had a molecular weight of about 60,000. A minor peak of inhibitory activity with a very low molecular weight was also detected but this material has not been studied further. also possible that the nonlinearity arises from negative cooperativity in binding, and further studies are required to exclude this possibility. The Kd value of 8 nM for the high affinity sites is in the range of that observed for other cell surface receptors (i.e., EGF) (4). We estimate that there are about 1-2 X 105high-affinity [3H]P(Bu)2 sites per cell, which is about 10-fold higher than the number of EGF receptor sites that we find on CREF cells (unpublished data). Our values for the kd and total number of high-affinity [3H]P(Bu)2 receptors in these intact rat fibroblasts are in good agreement with the values obtained with crude membrane preparations from avian fibroblasts or mouse epidermis (6, 7) . Thus, various species and cell types contain similar membrane-associated receptors for the phorbol esters, a finding consistent with evidence that diverse cell types show similar structure-function requirements when tested for biologic responses with a series of phorbol esters and related plant diterpenes (1) (2) (3) .
Several known growth factors and certain other membrane active compounds failed to inhibit [3H]P(Bu)2-receptor binding. However, calf, human, rhesus monkey, and rat sera were highly inhibitory, as were certain other biologic fluids and tissue extracts (Table 2) . We have obtained evidence that serum contains a specific factor(s) that inhibits [3H]P(Bu)2, that the major factor is a neutral or slightly acidic protein with a molecular weight in the range of 60,000, and-that this factor is not albumin. This factor has been purified about 135-fold. Once a more purified material has been obtained, it should be possible to determine if this substance exerts its inhibitory effect by competing directly with [3H]P(Bu)2 for binding to the same set of cellular receptors, by binding [3H]P(Bu)2 itself, or by some other mechanism. It will also be of interest to determine whether this substance induces biologic effects similar to those of the phorbol esters or whether it antagonizes the action of these tumor promoters.
